Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joan-ramon Laporte

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Drug Safety|August 9, 2002
Regulatory decisions in a globalised world: the domino effect of phenylpropanolamine withdrawal in Latin AmericaAlbert Figueras, Joan-Ramon Laporte
Bulletin De L'Academie Nationale De Medecine|August 2, 2016
[Pharmacoepidemiology: lights and shadows]Joan-ramon Laporte, Eduardo Diogene
Medicina Clinica|March 23, 2004
[News about therapeutic use of Cannabis and endocannabinoid system]Marta Duran, Joan-Ramon Laporte, Dolors Capellà
Medicina Clinica|April 12, 2002
[First spontaneous reports of adverse reactions to the new selective COX-2 non-steroidal anti-inflammatory drugs]Consuelo Pedrós, Gloria Cereza, Joan-Ramon Laporte
Drug Safety|February 1, 2002
Case-population studies in pharmacoepidemiologyDolors Capellà, Consuelo Pedrós, Xavier Vidal, et al.
Drug Safety|July 3, 2002
Therapeutic ineffectiveness: heads or tails?Albert Figueras, Consuelo Pedrós, Mabel Valsecia, et al.
Archives of Internal Medicine|April 27, 2005
Population-based drug-induced agranulocytosisLuisa Ibáñez, Xavier Vidal, Elena Ballarín, et al.
Journal of Hepatology|October 26, 2002
Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugsLuisa Ibáñez, Eulàlia Pérez, Xavier Vidal, et al.
European Journal of Clinical Pharmacology|December 8, 2004
Agranulocytosis associated with dipyrone (metamizol)Luisa Ibáñez, Xavier Vidal, Elena Ballarín, et al.
Pharmacoepidemiology and Drug Safety|May 10, 2002
Health needs, drug registration and control in less developed countries--the Peruvian caseAlbert Figueras, Susana Vasquez, Josep-Maria Arnau, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Drug Safety|August 9, 2002
Regulatory decisions in a globalised world: the domino effect of phenylpropanolamine withdrawal in Latin AmericaAlbert Figueras, Joan-Ramon Laporte
Bulletin De L'Academie Nationale De Medecine|August 2, 2016
[Pharmacoepidemiology: lights and shadows]Joan-ramon Laporte, Eduardo Diogene
Medicina Clinica|March 23, 2004
[News about therapeutic use of Cannabis and endocannabinoid system]Marta Duran, Joan-Ramon Laporte, Dolors Capellà
Medicina Clinica|April 12, 2002
[First spontaneous reports of adverse reactions to the new selective COX-2 non-steroidal anti-inflammatory drugs]Consuelo Pedrós, Gloria Cereza, Joan-Ramon Laporte
Drug Safety|February 1, 2002
Case-population studies in pharmacoepidemiologyDolors Capellà, Consuelo Pedrós, Xavier Vidal, et al.
Drug Safety|July 3, 2002
Therapeutic ineffectiveness: heads or tails?Albert Figueras, Consuelo Pedrós, Mabel Valsecia, et al.
Archives of Internal Medicine|April 27, 2005
Population-based drug-induced agranulocytosisLuisa Ibáñez, Xavier Vidal, Elena Ballarín, et al.
Journal of Hepatology|October 26, 2002
Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugsLuisa Ibáñez, Eulàlia Pérez, Xavier Vidal, et al.
European Journal of Clinical Pharmacology|December 8, 2004
Agranulocytosis associated with dipyrone (metamizol)Luisa Ibáñez, Xavier Vidal, Elena Ballarín, et al.
Pharmacoepidemiology and Drug Safety|May 10, 2002
Health needs, drug registration and control in less developed countries--the Peruvian caseAlbert Figueras, Susana Vasquez, Josep-Maria Arnau, et al.
Pageof 4